170 related articles for article (PubMed ID: 32297656)
1. Neutrophils expressing lysyl oxidase-like 4 protein are present in colorectal cancer liver metastases resistant to anti-angiogenic therapy.
Palmieri V; Lazaris A; Mayer TZ; Petrillo SK; Alamri H; Rada M; Jarrouj G; Park WY; Gao ZH; McDonald PP; Metrakos P
J Pathol; 2020 Jun; 251(2):213-223. PubMed ID: 32297656
[TBL] [Abstract][Full Text] [Related]
2. Different Forms of Tumor Vascularization and Their Clinical Implications Focusing on Vessel Co-option in Colorectal Cancer Liver Metastases.
Haas G; Fan S; Ghadimi M; De Oliveira T; Conradi LC
Front Cell Dev Biol; 2021; 9():612774. PubMed ID: 33912554
[TBL] [Abstract][Full Text] [Related]
3. Vessel co-option is common in human lung metastases and mediates resistance to anti-angiogenic therapy in preclinical lung metastasis models.
Bridgeman VL; Vermeulen PB; Foo S; Bilecz A; Daley F; Kostaras E; Nathan MR; Wan E; Frentzas S; Schweiger T; Hegedus B; Hoetzenecker K; Renyi-Vamos F; Kuczynski EA; Vasudev NS; Larkin J; Gore M; Dvorak HF; Paku S; Kerbel RS; Dome B; Reynolds AR
J Pathol; 2017 Feb; 241(3):362-374. PubMed ID: 27859259
[TBL] [Abstract][Full Text] [Related]
4. Immune phenotype and histopathological growth pattern in patients with colorectal liver metastases.
Stremitzer S; Vermeulen P; Graver S; Kockx M; Dirix L; Yang D; Zhang W; Stift J; Wrba F; Gruenberger T; Lenz HJ; Scherer SJ
Br J Cancer; 2020 May; 122(10):1518-1524. PubMed ID: 32205863
[TBL] [Abstract][Full Text] [Related]
5. Lysyl Oxidase-Like 4 Fosters an Immunosuppressive Microenvironment During Hepatocarcinogenesis.
Tan HY; Wang N; Zhang C; Chan YT; Yuen MF; Feng Y
Hepatology; 2021 Jun; 73(6):2326-2341. PubMed ID: 33068461
[TBL] [Abstract][Full Text] [Related]
6. Runt related transcription factor-1 plays a central role in vessel co-option of colorectal cancer liver metastases.
Rada M; Kapelanski-Lamoureux A; Petrillo S; Tabariès S; Siegel P; Reynolds AR; Lazaris A; Metrakos P
Commun Biol; 2021 Aug; 4(1):950. PubMed ID: 34376784
[TBL] [Abstract][Full Text] [Related]
7. Molecular differences of angiogenic versus vessel co-opting colorectal cancer liver metastases at single-cell resolution.
Fleischer JR; Schmitt AM; Haas G; Xu X; Zeisberg EM; Bohnenberger H; Küffer S; Teuwen LA; Karras PJ; Beißbarth T; Bleckmann A; Planque M; Fendt SM; Vermeulen P; Ghadimi M; Kalucka J; De Oliveira T; Conradi LC
Mol Cancer; 2023 Jan; 22(1):17. PubMed ID: 36691028
[TBL] [Abstract][Full Text] [Related]
8. Tumor microenvironment conditions that favor vessel co-option in colorectal cancer liver metastases: A theoretical model.
Rada M; Lazaris A; Kapelanski-Lamoureux A; Mayer TZ; Metrakos P
Semin Cancer Biol; 2021 Jun; 71():52-64. PubMed ID: 32920126
[TBL] [Abstract][Full Text] [Related]
9. International consensus guidelines for scoring the histopathological growth patterns of liver metastasis.
van Dam PJ; van der Stok EP; Teuwen LA; Van den Eynden GG; Illemann M; Frentzas S; Majeed AW; Eefsen RL; Coebergh van den Braak RRJ; Lazaris A; Fernandez MC; Galjart B; Laerum OD; Rayes R; Grünhagen DJ; Van de Paer M; Sucaet Y; Mudhar HS; Schvimer M; Nyström H; Kockx M; Bird NC; Vidal-Vanaclocha F; Metrakos P; Simoneau E; Verhoef C; Dirix LY; Van Laere S; Gao ZH; Brodt P; Reynolds AR; Vermeulen PB
Br J Cancer; 2017 Nov; 117(10):1427-1441. PubMed ID: 28982110
[TBL] [Abstract][Full Text] [Related]
10. Clinical implications and mechanism of histopathological growth pattern in colorectal cancer liver metastases.
Kong BT; Fan QS; Wang XM; Zhang Q; Zhang GL
World J Gastroenterol; 2022 Jul; 28(26):3101-3115. PubMed ID: 36051338
[TBL] [Abstract][Full Text] [Related]
11. Tissue inhibitor of matrix metalloproteinase-1 expression in colorectal cancer liver metastases is associated with vascular structures.
Illemann M; Eefsen RH; Bird NC; Majeed A; Osterlind K; Laerum OD; Alpízar-Alpízar W; Lund IK; Høyer-Hansen G
Mol Carcinog; 2016 Feb; 55(2):193-208. PubMed ID: 25594187
[TBL] [Abstract][Full Text] [Related]
12. [Value of histopathological growth pattern in predicting 3-year progression free survival after operation in patients with liver metastasis of colorectal cancer].
Zhang YL; He HJ; Cheng J; Shen DH
Zhonghua Bing Li Xue Za Zhi; 2021 Jan; 50(1):26-31. PubMed ID: 33396983
[No Abstract] [Full Text] [Related]
13. Angiogenic desmoplastic histopathological growth pattern as a prognostic marker of good outcome in patients with colorectal liver metastases.
Galjart B; Nierop PMH; van der Stok EP; van den Braak RRJC; Höppener DJ; Daelemans S; Dirix LY; Verhoef C; Vermeulen PB; Grünhagen DJ
Angiogenesis; 2019 May; 22(2):355-368. PubMed ID: 30637550
[TBL] [Abstract][Full Text] [Related]
14. Derepression of LOXL4 inhibits liver cancer growth by reactivating compromised p53.
Shao J; Lu J; Zhu W; Yu H; Jing X; Wang YL; Wang X; Wang XJ
Cell Death Differ; 2019 Nov; 26(11):2237-2252. PubMed ID: 30728460
[TBL] [Abstract][Full Text] [Related]
15. Replacement and desmoplastic histopathological growth patterns in cutaneous melanoma liver metastases: frequency, characteristics, and robust prognostic value.
Barnhill R; van Dam PJ; Vermeulen P; Champenois G; Nicolas A; Rawson RV; Wilmott JS; Thompson JF; Long GV; Cassoux N; Roman-Roman S; Busam KJ; Scolyer RA; Lazar AJ; Lugassy C
J Pathol Clin Res; 2020 Jul; 6(3):195-206. PubMed ID: 32304183
[TBL] [Abstract][Full Text] [Related]
16. LOXL4 knockdown enhances tumor growth and lung metastasis through collagen-dependent extracellular matrix changes in triple-negative breast cancer.
Choi SK; Kim HS; Jin T; Moon WK
Oncotarget; 2017 Feb; 8(7):11977-11989. PubMed ID: 28060764
[TBL] [Abstract][Full Text] [Related]
17. Glycolysis gene expression analysis and selective metabolic advantage in the clinical progression of colorectal cancer.
Graziano F; Ruzzo A; Giacomini E; Ricciardi T; Aprile G; Loupakis F; Lorenzini P; Ongaro E; Zoratto F; Catalano V; Sarti D; Rulli E; Cremolini C; De Nictolis M; De Maglio G; Falcone A; Fiorentini G; Magnani M
Pharmacogenomics J; 2017 Jun; 17(3):258-264. PubMed ID: 26927284
[TBL] [Abstract][Full Text] [Related]
18. Preoperative systemic chemotherapy alters the histopathological growth patterns of colorectal liver metastases.
Nierop PM; Höppener DJ; Buisman FE; van der Stok EP; Galjart B; Balachandran VP; Jarnagin WR; Kingham TP; Shia J; Mauer M; Nordlinger B; Julié C; Groot Koerkamp B; Doukas M; Vermeulen PB; Grünhagen DJ; D'Angelica MI; Verhoef C
J Pathol Clin Res; 2022 Jan; 8(1):48-64. PubMed ID: 34480530
[TBL] [Abstract][Full Text] [Related]
19. Differential histopathologic parameters in colorectal cancer liver metastases resected after triplets plus bevacizumab or cetuximab: a pooled analysis of five prospective trials.
Cremolini C; Milione M; Marmorino F; Morano F; Zucchelli G; Mennitto A; Prisciandaro M; Lonardi S; Pellegrinelli A; Rossini D; Bergamo F; Aprile G; Urbani L; Morelli L; Schirripa M; Cardellino GG; Fassan M; Fontanini G; de Braud F; Mazzaferro V; Falcone A; Pietrantonio F
Br J Cancer; 2018 Apr; 118(7):955-965. PubMed ID: 29531324
[TBL] [Abstract][Full Text] [Related]
20. Vascularization of colorectal carcinoma liver metastasis: insight into stratification of patients for anti-angiogenic therapies.
Lazaris A; Amri A; Petrillo SK; Zoroquiain P; Ibrahim N; Salman A; Gao ZH; Vermeulen PB; Metrakos P
J Pathol Clin Res; 2018 Jul; 4(3):184-192. PubMed ID: 29654716
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
